Jozefien Buyze

Beerse, VLG, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 88 publications

Erratum to "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study" [European Neuropsychopharmacology 107 (2026) 112801].

Erratum to "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study" [European Neuropsychopharmacology 107 (2026) 112801].

Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

Published: August 27, 2026

Response to: Commentary on "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study".

Response to: Commentary on "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study".

Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

Published: May 22, 2026

Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study.

Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study.

Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

Published: October 31, 2025

Improvements in health-related quality of life with esketamine nasal spray versus quetiapine extended release.

Improvements in health-related quality of life with esketamine nasal spray versus quetiapine extended release.

Journal: European psychiatry : the journal of the Association of European Psychiatrists

Published: October 14, 2025

A plain language summary of LocoMMotion - an observational study of treatments used for pretreated multiple myeloma.

A plain language summary of LocoMMotion - an observational study of treatments used for pretreated multiple myeloma.

Journal: Future oncology (London, England)

Published: October 08, 2025

Developing a clinical case definition for Chikungunya fever in the Democratic Republic of the Congo.

Developing a clinical case definition for Chikungunya fever in the Democratic Republic of the Congo.

Journal: PloS one

Published: October 04, 2025

Outcomes of Patients With Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma From the Pooled LocoMMotion and MoMMent Studies.

Outcomes of Patients With Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma From the Pooled LocoMMotion and MoMMent Studies.

Journal: Clinical lymphoma, myeloma & leukemia

Published: February 03, 2025

Esketamine Nasal Spray vs Quetiapine Extended-Release: Examining Work Productivity Loss and Related Costs in Patients With Treatment-Resistant Depression.

Esketamine Nasal Spray vs Quetiapine Extended-Release: Examining Work Productivity Loss and Related Costs in Patients With Treatment-Resistant Depression.

Journal: The Journal of clinical psychiatry

Published: February 03, 2025

Treatment of Plaque Psoriasis with Guselkumab Reduces Systemic Inflammatory Burden as Measured by Neutrophil/Lymphocyte Ratio, Platelet/Lymphocyte Ratio, and Monocyte/Lymphocyte Ratio: A post hoc Analysis of Three Randomised Clinical Trials.

Treatment of Plaque Psoriasis with Guselkumab Reduces Systemic Inflammatory Burden as Measured by Neutrophil/Lymphocyte Ratio, Platelet/Lymphocyte Ratio, and Monocyte/Lymphocyte Ratio: A post hoc Analysis of Three Randomised Clinical Trials.

Journal: Dermatology (Basel, Switzerland)

Published: July 05, 2024

Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial.

Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial.

Journal: Dermatology and therapy

Published: May 14, 2024

Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression.

Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression.

Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

Published: April 02, 2024

Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials.

Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials.

Journal: Dermatology and therapy

Published: January 24, 2024

Showing 1-12 of 88

Last Updated: 09/26/2026